Onco Wiki / Indication

Multiple Myeloma · line 1 · Bortezomib + Lenalidomide + Dexamethasone (VRd), 4-6 induction cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackstandard
Linked regimenREG-VRD
IDIND-MM-1L-VRD
TypeIndication
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesDIS-MM
SourcesSRC-NCCN-MM-2025

Notes

STUB — requires clinical co-lead signoff before publication. Standard track for the MM 1L two-plan output (CHARTER §2). Transplant eligibility is assessed separately and shapes total cycle count + post-induction pathway, but does not change the induction regimen at this layer.

Used By

Algorithms

Contraindications

Handbook Chapters

Handbook Questions

Indication

Red flag